comment: immunotherapy combo increases median survival in advanced melanoma
Published 9 years ago • 44 plays • Length 3:06Download video MP4
Download video MP3
Similar videos
-
6:51
success for ipilimumab and nivolumab combo in advanced melanoma
-
1:13
checkmate 067: nivolumab plus ipilimumab combination therapy in advanced melanoma
-
8:28
success for ipilimumab and nivolumab combo in advanced melanoma
-
24:18
pembrolizumab is better than ipilimumab for advanced melanoma in phase iii trial
-
2:03
immunotherapy before targeted therapy significantly improves advanced melanoma survival
-
4:57
investigational immunotherapy drug combo safe with early signs of effectiveness in advanced melanoma
-
2:48
checkmate067 outcomes: nivolumab plus ipilimumab in advanced melanoma
-
2:53
multiorgan toxicity following combination immunotherapy treatment in melanoma
-
4:05
vaccine-immunotherapy combo for high risk melanoma: new data on distant metastasis-free survival
-
2:14
combination of two immunotherapies brings advanced melanoma survival rate to 50% for first time
-
7:48
immunotherapy combinations in advanced melanoma
-
35:43
immunotherapy: yervoy and beyond
-
0:37
tils prolong pfs compared with pembrolizumab in advanced melanoma
-
4:07
phase ii trial of ipilimumab-nivolumab combo shows promise in advanced melanoma
-
1:59
dr. sznol on combining nivolumab and ipilimumab for the treatment of advanced melanoma
-
5:13
dabrafenib plus trametinib improves melanoma patients’ survival
-
1:52
comment: pd-1 targeting mk-3475 gives long-term responses in melanoma
-
5:10
new drugs and new trials in melanoma
-
7:41
nivolumab potentially superior to standard chemo in advanced melanoma